Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Drug Resistance

  Free Subscription


21.11.2019

2 Antimicrob Agents Chemother
4 Clin Infect Dis
1 Infect Control Hosp Epidemiol
1 Int J Antimicrob Agents
2 J Antimicrob Chemother
1 J Infect Dis
1 J Virol
4 Nat Med
1 PLoS Comput Biol
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Antimicrob Agents Chemother

  1. WATSON A, Sauve K, Cassino C, Schuch R, et al
    Exebacase demonstrates in vitro synergy with a broad range of antibiotics against both methicillin-resistant and methicillin-susceptible Staphylococcus aureus.
    Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01885.
    PubMed     Text format     Abstract available

  2. CASTANHEIRA M, Doyle TB, Kantro V, Mendes RE, et al
    Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals During 2016-2018.
    Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01951.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  3. ECHOLS R, Ariyasu M, Nagata TD
    Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
    Clin Infect Dis. 2019;69.
    PubMed     Text format     Abstract available

  4. BONOMO RA
    Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
    Clin Infect Dis. 2019;69.
    PubMed     Text format     Abstract available

  5. NORDMANN P, Poirel L
    Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.
    Clin Infect Dis. 2019;69.
    PubMed     Text format     Abstract available

  6. DOI Y
    Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
    Clin Infect Dis. 2019;69.
    PubMed     Text format     Abstract available


    Infect Control Hosp Epidemiol

  7. LERNER AO, Abu-Hanna J, Carmeli Y, Schechner V, et al
    Environmental contamination by carbapenem-resistant Acinetobacter baumannii: The effects of room type and cleaning methods.
    Infect Control Hosp Epidemiol. 2019 Nov 14:1-6. doi: 10.1017/ice.2019.
    PubMed     Text format     Abstract available


    Int J Antimicrob Agents

  8. AGYEMAN AA, Bergen PJ, Rao GG, Nation RL, et al
    A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections.
    Int J Antimicrob Agents. 2019 Oct 30. pii: S0924-8579(19)30294.
    PubMed     Text format     Abstract available


    J Antimicrob Chemother

  9. ZHANG Y, Jin L, Ouyang P, Wang Q, et al
    Evolution of hypervirulence in carbapenem-resistant Klebsiella pneumoniae in China: a multicentre, molecular epidemiological analysis.
    J Antimicrob Chemother. 2019 Nov 12. pii: 5622907. doi: 10.1093.
    PubMed     Text format     Abstract available

  10. SAVOLDI A, Carrara E, Gladstone BP, Azzini AM, et al
    Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list.
    J Antimicrob Chemother. 2019;74:3619-3625.
    PubMed     Text format     Abstract available


    J Infect Dis

  11. OLESEN SW, Torrone EA, Papp JR, Kirkcaldy RD, et al
    Azithromycin Susceptibility Among Neisseria gonorrhoeae Isolates and Seasonal Macrolide Use.
    J Infect Dis. 2019;219:619-623.
    PubMed     Text format     Abstract available


    J Virol

  12. YOSHIDA T, Shiraishi T, Hagiwara-Komoda Y, Komatsu K, et al
    The Plant Noncanonical Antiviral Resistance Protein JAX1 Inhibits Potexviral Replication by Targeting the Viral RNA-Dependent RNA Polymerase.
    J Virol. 2019;93.
    PubMed     Text format     Abstract available


    Nat Med

  13. DIDELOT X, Pouwels KB
    Machine-learning-assisted selection of antibiotic prescription.
    Nat Med. 2019;25:1033-1034.
    PubMed     Text format    

  14. DOAN T, Hinterwirth A, Worden L, Arzika AM, et al
    Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution.
    Nat Med. 2019;25:1370-1376.
    PubMed     Text format     Abstract available

  15. YANT SR, Mulato A, Hansen D, Tse WC, et al
    A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model.
    Nat Med. 2019;25:1377-1384.
    PubMed     Text format     Abstract available

  16. BHUTTA ZA
    The benefits and risks of mass antibiotic use for reducing child mortality.
    Nat Med. 2019;25:1332-1334.
    PubMed     Text format    


    PLoS Comput Biol

  17. DUVAL A, Obadia T, Boelle PY, Fleury E, et al
    Close proximity interactions support transmission of ESBL-K. pneumoniae but not ESBL-E. coli in healthcare settings.
    PLoS Comput Biol. 2019;15:e1006496.
    PubMed     Text format     Abstract available


    PLoS One

  18. GARCIA PK, Annamalai T, Wang W, Bell RS, et al
    Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound.
    PLoS One. 2019;14:e0207733.
    PubMed     Text format     Abstract available

  19. VICETTI MIGUEL CP, Mejias A, Leber A, Sanchez PJ, et al
    A decade of antimicrobial resistance in Staphylococcus aureus: A single center experience.
    PLoS One. 2019;14:e0212029.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: